Answers are grounded in this paper and cite their sources.
Alcohol-associated liver disease (ALD) remains a major global etiology of cirrhosis and liver-related mortality. The newly proposed nomenclature for metabolic- and alcohol-associated liver disease (MetALD) blurs the traditional boundary between ALD and metabolic dysfunction-associated steatotic liver disease (MASLD), posing substantial challenges for precise non-invasive diagnosis. Liver biopsy is invasive, while routine serum biochemical biomarkers exhibit insufficient sensitivity and specificity for etiologic discrimination among steatotic liver disease subtypes. Circulating microRNAs (miRNAs), stably packaged within extracellular vesicles (EVs), or bound to protein/lipoprotein complexes, have emerged as candidate biomarkers of hepatocyte injury. Whether they additionally function as intercellular signaling molecules in ALD remains predominantly unvalidated. This review synthesizes recent preclinical and clinical evidence for circulating miRNAs in ALD through a three-category evidence framework: (i) intracellular/tissue regulation within the cell of origin, (ii) altered circulating abundance as biomarkers of injury, and (iii) experimentally demonstrated functional transfer to recipient cells. Notably, no circulating miRNA study has specifically stratified MetALD as a distinct cohort. We discuss major practical barriers for clinical application, and provide perspectives for improved biomarker design and miRNA-oriented therapeutics.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: